🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523840-11-00
Authorised Phase II

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

2025-523840-11-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Leon Berard
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Pathological Conditions, Signs and Symptoms
Decision date
17/07/2026
Enrollment target
50
Sites
France

Condition studied

Children with refractory symptoms

Investigational medicinal product(s)

MIDAZOLAM

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

To describe the efficacy of proportional sedation using transmucosal midazolam in pediatric palliative patients presenting with refractory symptoms

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523840-11-00 on CTIS ↗ ← All trials in the EU